Innate Pharma S.A. Reports SEC Filing Form 6-K on January 16, 2025

Here is the key information extracted from the provided section of the financial report:

1. Form Type: The report is filed as Form 6-K, which is generally used by foreign private issuers to provide current reports to the SEC.
2. Date of Report: January 16, 2025.
3. Commission File Number: 001-39084.
4. Registrant: Innate Pharma S.A.

• Address: 117 Avenue de Luminy, BP 30191, 13009 Marseille, France.
• Contact Number: +33 (0) 4 30 30 30.

5. Filing Status: The registrant indicates that it files annual reports under Form 20-F.
6. Incorporation by Reference: This report and Exhibit 99.1 will be incorporated by reference into registration statements filed previously with the SEC, specifically Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031).
7. Exhibit: The report includes a press release dated January 16, 2025, listed as Exhibit 1.1.
8. Signatory: The report is signed by Jonathan Dickinson, who holds the titles of Chairman of the Executive Board and Chief Executive Officer, with the signing date being January 16, 2025.

Insights:

• Regulatory Compliance: The filing adheres to requirements for foreign private issuers, ensuring transparency and compliance with SEC regulations.
• Corporate Governance: The signoff by the CEO indicates active leadership oversight and accountability for the information disclosed in the report.
• Ongoing Reporting: The use of Form 20-F suggests that Innate Pharma S.A. is committed to providing comprehensive annual information to investors, which is important for maintaining investor confidence and regulatory compliance.

This report appears to be part of a standardized process for keeping stakeholders informed about the company's operations and regulatory status.